DPP4 and type 2 diabetes mellitus: Anagliptin, a DPP-4 inhibitor launched in 2012, reportedly lowered LDL cholesterol levels in a long-term phase III trial [13] and, since then, several studies have confirmed its beneficial effect on lipid metabolism by showing that the drug decreases serum cholesterol and triglyceride levels in patients with type 2 diabetes [14, 15].